Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $2.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|
| Traversa Sergio | Chief Executive Officer | Dec 15 '25 | Buy | $4.12 | 27,500 | $113,300 | 1,300,000 | Dec 16 09:30 AM |
| Shenouda Maged | Chief Financial Officer | Dec 15 '25 | Buy | $4.12 | 11,665 | $48,060 | 800,000 | Dec 16 09:30 AM |
| Shenouda Maged | Chief Financial Officer | Nov 05 '25 | Buy | $2.20 | 500,000 | $1,100,000 | 788,335 | Nov 06 07:30 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.